Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease ...

Aurion will operate as a separate company with full support from Alcon to advance its clinical-stage allogeneic cell therapy asset, AURN001, into Phase 3 for corneal edema secondary to corneal ...

EndoArt, the world's first artificial endothelial implant, has revolutionized the management of corneal edema, offering an alternative to traditional corneal transplants. With a staggering global ...

Alcon acquired a majority interest in Aurion Biotech, a clinical-stage company developing advanced cell therapies to treat eye diseases. Terms of the deal weren't disclosed.

Alcon has acquired a majority interest in Aurion Biotech, according to a press release. Aurion will operate as a separate company but will use support from Alcon to take AURN001, its clinical-stage ...

The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...

The first in-human trials of an implantable device shows favorable safety and effectiveness in the treatment of corneal edema. The first in-human trials for an artificial lamellar implant (EndoArt, ...

Alcon is one of the leading visioncare companies in the world, with a record of successful product development, and it will continue to launch technically superior products.

Medically reviewed by Elizabeth Barnes, RDN Chondroitin sulfate is a relatively safe supplement used to support joint and ...

Gonioscopy-assisted transluminal trabeculotomy effectively reduces IOP and medication burden in patients with angle recession glaucoma.